Model-based lamotrigine clearance changes during pregnancy: Clinical implication

Annals of Clinical and Translational Neurology

Volumn 1, Issue 2, 2014, Pages 99-106

  Polepally, Akshanth R ^a   Pennell, Page B ^b   Brundage, Richard C ^a   Stowe, Zachary N ^c   Newport, Donald J ^d,e   Viguera, Adele C ^f   Ritchie, James C ^e   Birnbaum, Angela K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE;

ADULT; ARTICLE; DRUG CLEARANCE; ELIMINATION HALF-LIFE; EPILEPSY; FEMALE; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL BLOOD; OBSERVATIONAL STUDY; PERINATAL PERIOD; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 84929297748     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.29     Document Type: Article

References (42)

1. Newport DJ, Stowe ZN, Viguera AC, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008;10:432-436.
2. Sabers A, Dam M, A-Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004;109:9-13.
3. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013;12:244-252.
4. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012;11:803-813.
5. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-1699.
6. Gedzelman ER, Meador KJ. Antiepileptic drugs in women with epilepsy during pregnancy. Ther Adv Drug Saf 2012;78:71-87.
7. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-617.
8. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004;161:608-620.
9. Fotopoulou C, Kretz R, Bauer S, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res 2009;85:60-64.
10. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008;70:2130-2136.
11. Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure 2008;17:199-202.
12. Ohman I, Beck O, Vitols S, Tomson T. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 2008;49:1075-1080.
13. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005;65:185-188.
14. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004;63:571-573.
15. Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004;62:292-295.
16. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002;59:251-255.
17. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000;41:709-713.
18. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997;38: 1039-1041.
19. Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia 2009;50:2163-2166.
20. Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73:142-149.
21. Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
22. Depot M, Powell JR, Messenheimer JA Jr, et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990;48:346-355.
23. Yuen W, Peck A. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Br J Clin Pharmacol 1988; 26:242.
24. Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
25. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DG, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-254.
26. Argikar UA, Remmel RP. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica 2009;39:355-363.
27. Rowland A, Elliot DJ, Williams JA, et al. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 2006;34:1055-1062.
28. Tephly TR, Green MD, Coffman BL, et al. Metabolism of endobiotics and xenobiotics by UDP-glucuronosyltransferase. Adv Pharmacol 1998;42:343-346.
29. Reimers A, Ostby L, Stuen I, Sundby E. Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term. Eur J Drug Metab Pharmacokinet 2011;35:79-82.
30. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005;46:1414-1417.
31. Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991;51:347-369.
32. Riedmann M, Rambeck B, Meijer JW. Quantitative simultaneous determination of eight common antiepileptic drugs and metabolites by liquid chromatography. Ther Drug Monit 1981;3:397-413.
33. Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol 1997;12(Suppl. 1):S10-S15.
34. Mallaysamy S, Johnson MG, Rao PG, et al. Population pharmacokinetics of lamotrigine in Indian epileptic patients. Eur J Clin Pharmacol 2012;69:43-52.
35. Rivas N, Buelga DS, Elger CE, et al. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 2008;30:483-489.
36. Chan V, Morris RG, Ilett KF, Tett SE. Population pharmacokinetics of lamotrigine. Ther Drug Monit 2001;23:630-635.
37. Grasela TH, Fiedler-Kelly J, Cox E, et al. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 1999;39:373-384.
38. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997;43:457-465.
39. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003;61:S35-S42.
40. Zhou J, Argikar UA, Remmel RP. Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes. Pharmacogenomics 2011;12:1671-1679.
41. Lopez M, Dorado P, Monroy N, et al. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. Drug Metabol Drug Interact 2011;26:5-12.
42. Chen H, Yang K, Choi S, et al. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos 2009;37:1841-1847.